06 mar: Aktietilbagekøbsprogram på DKK 400 mio. igangsættes
06 mar: Investeringsselskabet Artha Optimum A/S – optagelse til handel af..
06-03-2019 14:25:00

Investor Expectations to Drive Momentum within Amarin, PulteGroup, LivaNova, Teva Pharmaceutical Industries, Viad, and Activision Blizzard — Discovering Underlying Factors of Influence

NEW YORK, March 06, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Amarin Corporation PLC (NASDAQ:AMRN), PulteGroup, Inc. (NYSE:PHM), LivaNova PLC (NASDAQ:LIVN), Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Viad Corp (NYSE:VVI), and Activision Blizzard, Inc (NASDAQ:ATVI), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

AMRN DOWNLOAD: https://Capital-Review.com/register/?so=AMRN

PHM DOWNLOAD: https://Capital-Review.com/register/?so=PHM

LIVN DOWNLOAD: https://Capital-Review.com/register/?so=LIVN

TEVA DOWNLOAD: https://Capital-Review.com/register/?so=TEVA

VVI DOWNLOAD: https://Capital-Review.com/register/?so=VVI

ATVI DOWNLOAD: https://Capital-Review.com/register/?so=ATVI

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Capital Review, available for free download at the links above, examine Amarin Corporation PLC (NASDAQ:AMRN), PulteGroup, Inc. (NYSE:PHM), LivaNova PLC (NASDAQ:LIVN), Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Viad Corp (NYSE:VVI), and Activision Blizzard, Inc (NASDAQ:ATVI) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice:

the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed March 4th, 2019. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

AMARIN CORPORATION PLC (AMRN) REPORT OVERVIEW

Amarin's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Amarin reported revenue of $77.33MM vs $53.87MM (up 43.56%) and analysts estimated basic earnings per share -$0.11 vs -$0.08. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Amarin reported revenue of $229.21MM vs $181.10MM (up 26.56%) and analysts estimated basic earnings per share -$0.39 vs -$0.25. Analysts expect earnings to be released on May 1st, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.08. The estimated EPS forecast for the next fiscal year is $0.25 and is expected to report on February 26th, 2020.

To read the full Amarin Corporation PLC (AMRN) report, download it here: https://Capital-Review.com/register/?so=AMRN

-----------------------------------------

PULTEGROUP, INC. (PHM) REPORT OVERVIEW

PulteGroup's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, PulteGroup reported revenue of $2,999.15MM vs $2,794.89MM (up 7.31%) and analysts estimated basic earnings per share $0.84 vs $0.25 (up 236.00%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, PulteGroup reported revenue of $10,188.33MM vs $8,577.69MM (up 18.78%) and analysts estimated basic earnings per share $3.56 vs $1.45 (up 145.52%). Analysts expect earnings to be released on April 23rd, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was $0.59. The estimated EPS forecast for the next fiscal year is $3.32 and is expected to report on February 4th, 2020.

To read the full PulteGroup, Inc. (PHM) report, download it here: https://Capital-Review.com/register/?so=PHM

-----------------------------------------

LIVANOVA PLC (LIVN) REPORT OVERVIEW

LivaNova's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, LivaNova reported revenue of $272.08MM vs $251.25MM (up 8.29%) and analysts estimated basic earnings per share -$0.15 vs $0.58. For the twelve months ended December 31st, 2017 vs December 31st, 2016, LivaNova reported revenue of $1,012.28MM vs $964.86MM (up 4.91%) and analysts estimated basic earnings per share -$0.52 vs -$1.29. Analysts expect earnings to be released on May 1st, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was $0.36. The estimated EPS forecast for the next fiscal year is $3.62 and is expected to report on February 26th, 2020.

To read the full LivaNova PLC (LIVN) report, download it here: https://Capital-Review.com/register/?so=LIVN

-----------------------------------------

TEVA PHARMACEUTICAL INDUSTRIES LTD. (TEVA) REPORT OVERVIEW

Teva Pharmaceutical Industries' Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Teva Pharmaceutical Industries reported revenue of $4,559.00MM vs $5,398.00MM (down 15.54%) and basic earnings per share -$2.88 vs -$11.41. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Teva Pharmaceutical Industries reported revenue of $18,854.00MM vs $22,385.00MM (down 15.77%) and analysts estimated basic earnings per share -$2.35 vs -$16.26. Analysts expect earnings to be released on May 2nd, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.91. The estimated EPS forecast for the next fiscal year is $2.56 and is expected to report on February 12th, 2020.

To read the full Teva Pharmaceutical Industries Ltd. (TEVA) report, download it here: https://Capital-Review.com/register/?so=TEVA

-----------------------------------------

VIAD CORP (VVI) REPORT OVERVIEW

Viad's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Viad reported revenue of $296.92MM vs $277.29MM (up 7.08%) and analysts estimated basic earnings per share -$0.12 vs -$1.06. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Viad reported revenue of $1,296.18MM vs $1,306.97MM (down 0.82%) and analysts estimated basic earnings per share $2.40 vs $2.83 (down 15.19%). Analysts expect earnings to be released on April 25th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.49. The estimated EPS forecast for the next fiscal year is $3.55 and is expected to report on February 6th, 2020.

To read the full Viad Corp (VVI) report, download it here: https://Capital-Review.com/register/?so=VVI

-----------------------------------------

ACTIVISION BLIZZARD, INC (ATVI) REPORT OVERVIEW

Activision Blizzard's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Activision Blizzard reported revenue of $2,382.00MM vs $2,042.00MM (up 16.65%) and analysts estimated basic earnings per share $0.85 vs -$0.78. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Activision Blizzard reported revenue of $7,500.00MM vs $7,017.00MM (up 6.88%) and analysts estimated basic earnings per share $2.38 vs $0.36 (up 561.11%). Analysts expect earnings to be released on May 2nd, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.34. The estimated EPS forecast for the next fiscal year is $2.59 and is expected to report on February 11th, 2020.

To read the full Activision Blizzard, Inc (ATVI) report, download it here: https://Capital-Review.com/register/?so=ATVI

-----------------------------------------

ABOUT CAPITAL REVIEW

Capital Review is a nationally recognized publisher of financial analysis, research reports, and exclusive market reporting. Institutional investors, registered brokers, professional traders, and personal investment advisers rely on Capital Review to quantify public company valuations, discover opportunity across asset classes, stay informed about market-moving events, and read exclusive analysis of important material developments. With 14 offices worldwide, Capital Review staffs and manages certified and registered financial professionals, including Chartered Financial Analyst® (CFA®) designation holders and FINRA® BrokerCheck® certified individuals with current and valid CRD® number designations, to enable continuous coverage of topics relevant to its regular active reader base.

REGISTERED MEMBER STATUS

Capital Review's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Capital Review's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Capital Review have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Capital Review's Compliance department by Phone, at +1 (410) 280-7496, or by E-mail at compliance@Capital-Review.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Capital Review, Capital Review members, and/or Capital Review affiliates are not responsible for any gains or losses that result from the opinions expressed. Capital Review makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Capital Review has not been compensated for the publication of this press release by any of the above mentioned companies. Capital Review is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:

Nicole Garrens, Media Department

Office: +1 (410) 280-7496

E-mail: media@Capital-Review.com

© 2019 Capital Review. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Capital-Review.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.

Relateret indhold
Relateret debat
20 aug - 
Teva udgør 0,13% af Berkshire's portefølje og er i øvri..
20 aug - 
Endo's chief legal officer, Matthew Maletta, called the..
20 aug - 
endo bure få medvind den kommende tid https://finance.y..
Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
14 aug
TEVA
Ja, TEVA er jo bare en dårlig historie at købe ind i. I Danmark er aktien (som alle jo ved) primært ..
16
14 aug
TEVA
Teva er ramt af mange dårlige nyheder og specielt frygten for en mulig tabt retsag og dertil kæmpe e..
6
14 aug
TEVA
idiot
4
20 aug
TEVA
Endo's chief legal officer, Matthew Maletta, called the settlement a "favorable outcome" and stresse..
2
15 aug
TEVA
Yes. WB uændret. Bill miller er en legendarisk investor, som jeg følger markedet. Han slår markedet ..
2
14 aug
TEVA
Teva er "dead man walking". Et skandale-selskab der ikke har livets ret. Kåre Schultz med sin 300+ m..
2
20 aug
TEVA
Teva udgør 0,13% af Berkshire's portefølje og er i øvrigt købt af den del der styres af Ted/Todd, hv..
1
20 aug
TEVA
nej men det er jo lignende sager der bl.a. har fået teva så lngt ned i kurs, altså følg nu lidt med...
1
20 aug
TEVA
Nej det er endo international der har fået en gid aftale /forlig i retten det smitter af på teva
1
20 aug
TEVA
https://finance.yahoo.com/news/teva-launch-generic-version-epipen-122331889.html
1

Fondsbørsmeddelelser

Pandora-topchef køber aktier for 12,3 mio. kr.

21-08-2019 12:38:56
Pandoras topchef, Alexander Lacik, har ligesom finansdirektør Anders Boyer købt op i smykkeselskabet.Lacik har erhvervet sig knap 50.000 Pandora-aktier til en samlet pris på omtrent 12,3 mio. kr., fremgår det onsdag af en fondsbørsmeddelelse.Stykprisen, topchefen har betalt for aktierne, løber derfor op i 247,3 kr.Onsdag ved middagstid koster en Pandora-aktie 292,90 kr. på børsen i København efter..

Fiat og Renault drøner i vejret efter rygter om mulig fusion

Relaterede nyheder
21-08-2019 12:08:08
En fusion af Italien og Frankrig kan tyde på mere end bare et kulinarisk mesterværk, da investorerne onsdag middag har sat tænderne i bilaktierne for Fiat og Renault.Franske Renault drøner i vejret med 4,4 pct., og italienske Fiat følger med i svinget med en stigning på 3,8 pct., efter rygter om at en mulig fusion mellem de to bilgiganter stadig kan være på tale.Ifølge Bloomberg News fortæller ano..

Netcompany/CEO: Vi vækster inden for de lovede rammer

21-08-2019 08:38:35
Netcompanys regnskab for andet kvartal af regnskabsåret 2019 viser overordnet set, at it-virksomheden har godt styr på forretningen.Det mener selskabets administrerende direktør, André Rogaczewski.- Kort sagt må vi sige, at vi har godt styr på forretningen. Vi leverer det, vi har lovet. Vi vækster inden for de rammer, vi har lovet. Vi har ansat en masse dygtige medarbejdere, og vi har en forretnin..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Pandora/Jyske Bank: Løfter anbefaling til "køb" og hæver kursmål
2
Pandora/Sydbank: Flere forhold har givet smykkeaktien vind i sejlene
3
Pandora-topchef køber aktier for 12,3 mio. kr.
4
Aktier/tendens: Pandora nærmer sig milepæl for året
5
Matas/markedsdeltager: Kæmpe nedtur en forsinket reaktion på regnskab

Relaterede aktiekurser

Teva Pharmaceutical Indu.. 7,205 2,8% Stigning i aktiekurs
Amarin Corporation plc -.. 16,20 5,0% Stigning i aktiekurs
Activision Blizzard Inc 49,27 1,0% Stigning i aktiekurs
PulteGroup Inc 32,71 0,2% Stigning i aktiekurs
Viad Corp 66,78 0,9% Stigning i aktiekurs
LivaNova PLC - Ordinary .. 81,19 0,4% Stigning i aktiekurs

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
21. august 2019 18:49:07
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190819.1 - EUROWEB5 - 2019-08-21 18:49:07 - 2019-08-21 18:49:07 - 1 - Website: OKAY